Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of MCLA-129 in advanced solid tumors
CTR20211039Phase 2Active
- Sponsor
- Betta Pharmaceuticals
- Start
- Sep 2021
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of pamvatamig in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), colorectal cancer (CRC), gastric adenocarcinoma, sponsored by Betta Pharmaceuticals. Started Sep 2021; status: active.
02
Drugs
pamvatamig
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)colorectal cancer (CRC)gastric adenocarcinoma
Beyond the preview
Go deeper on CTR20211039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211039.